Product Name:
VEGFR2-pY1054
Product Number:
ab-pk852
Target Full Name: Vascular endothelial growth factor receptor 2 ; Vascular endothelial growth factor receptor-tyrosine kinase 2 (Flk1)
Target Alias: A type III receptor tyrosine kinase; CD309; FLK1; Kinase insert domain receptor; Protein-tyrosine kinase receptor Flk-1; Vascular endothelial growth factor receptor 2; VEGFR; VEGFR2; VGR2; CD309; CCDS3497.1; ENSG00000128052
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK852
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y1054
Protein UniProt: P35968
Protein SigNET: P35968
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human VEGFR2 (KDR) sequence peptide Cat. No.: PE-04AGM99
Antibody Immunogen Sequence: RDI(pY)KDP(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R1051 to P1057; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues R1051 to P1057; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with recombinant human VEGFR2 on protein dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 170-200 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: Strong immunoreactivity on protein dot blots with recombinant human VEGFR3 and medium immunoreactivity with VEGFR1, which feature nearly identical phosphosite sequences. Almost no significant cross-reactivities detected in HepG2 and T98G cells, except a 75 kDa in HepG2 cells.
Related Product 1: VEGFR2-pY1054 blocking peptide
Related Product 2: VEGFR2-1 pan-specific antibody (Cat. No.: AB-NK245-1)
Related Product 3: VEGFR2-2 pan-specific antibody (Cat. No.: AB-NK245-2)
Related Product 4: VEGFR2-3 pan-specific antibody (Cat. No.: AB-NK245-3)
Scientific Background: VEGFR2 (KDR, FLK1) is a protein-tyrosine kinase of the TK group and VEGFR (vascular endothelial growth factor receptor) family. It is a receptor kinase that binds VEGFA, VEGFC, and VEGFD, and has an essential function in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. VEGFR2 activation promotes the proliferation, survival, migration, and differentiation of endothelial cells. It is activated by binding VEGF, which induces dimerization and autophosphorylation at the following phosphosites, which all contribute to increased phosphotransferase activity. In addition, autophosphorylation of Y801 induces interaction with PIK3R1, autophosphorylation of Y951 and Y1008 induces interaction with PLCg1, autophosphorylation of Y1054, Y996 and Y1059 induces interaction with PLCg1, and autophosphorylation of Y1175 induces interaction with PLCg1, Shb, Shc1 and Shc2. KDR mediates the activation of the ERK1/2 MAP kinase intracellular signalling pathways. VEGFR2 appears to be an oncoprotein (OP). Mutations in the VEGFR2 gene have been observed in patients with hemangioma. Significantly higher VEGFR2 expression was observed in metastatic as compared to non-metastatic human colon cancer cell lines, which directly correlated with increased neovascularization and tumour cell proliferation. Elevated VEGFR2 expression was also correlated with blood vessel count in human intestinal-type gastric cancers, and in tumour cells in primary and metastatic ovarian carcinomas. VEGF signalling is vital to the early stages of tumour progression in mouse models of squamous skin tumours. In addition, inhibition of VEGFR2 resulted in tumour regression through decreased microvasculature and impaired ability to maintain the stem-like characteristic of the tumour cells.
